Bharat Biotech mulls IPO to raise over USD 500 million
New Delhi: The developer of Covid-19 vaccine Covaxin, Bharat Biotech is considering an initial public offering that could raise over USD 500 million, according to sources cited by multiple reports. Discussions are underway including key aspects of the proposed share sale, including size and timing, they said. Bharat Biotech plans Rs 200–250 crore of capital…